We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Light-Activated Drug Transport System Based on RBC Carriers

By LabMedica International staff writers
Posted on 18 Jan 2017
Print article
Image: A scanning electron micrograph (SEM) image of human red blood cells (Photo courtesy of MPI).
Image: A scanning electron micrograph (SEM) image of human red blood cells (Photo courtesy of MPI).
A novel system for precise delivery of toxic anticancer drugs is based on the use of red blood cells as carriers to transport immobilized drug complexes that are released at specific sites upon exposure to light.

Investigators at the University of North Carolina found that membrane-permeable drugs could be rendered membrane impermeable by covalent attachment to cobalamin (Cbl) through a photocleavable linker. These Cbl-drug conjugates could be trapped within lipid-enclosed compartments in the dark. The investigators adapted red blood cells for this purpose. Subsequent exposure to light broke the Cbl-drug bond and enabled the secretion of the bioactive species from the red blood cells.

The investigators reported in the December 23, 2016, issue of the journal Angewandte Chemie that photorelease of the trapped drug was triggered by wavelengths in the red, far-red, and near-IR regions, which could be pre-assigned by affixing a fluorophore with the desired excitation wavelength to the Cbl-drug conjugate. Breaking the weak energy bond between vitamin B12 and the drug was facilitated by the attached fluorescent molecule, which captured and focused the long wavelength light that ultimately cut the bond between the drug and the vitamin carrier.

"The problem is when you start using four or five very toxic drugs you are going to have intolerable side effects," said senior author Dr. David Lawrence, professor of pharmacy at the University of North Carolina. "However, by focusing powerful drugs at a specific site, it may be possible to significantly reduce or eliminate the side effects that commonly accompany cancer chemotherapy. Using light to treat a disease site has a lot of benefits beyond the "is not-that-cool" factor. Those benefits could include avoiding surgery and the risk of infection, making anesthesia unnecessary and allowing people to treat themselves by shining a light on a problem area, such as an arthritic knee."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.